DYADIC INTERNATIONAL INC Overview
Pro stress-test →Dyadic is a global biotechnology company using proprietary microbial platforms to produce recombinant, animal-free proteins and enzymes sold or licensed to partners across life sciences, food and nutrition, and bio-industrial markets for non-therapeutic applications. The company is transitioning from R&D to commercial operations, with multiple product launches underway.
Strategic Profile
Pro stress-test →Dyadic offers the Dapibus Protein Production Platform (a proprietary expression system for non-animal proteins and enzymes) and C1 Protein Production Platform (a thermophilic fungal platform for large-scale protein production). The company is executing a strategy to transition into a commercially driven organization by broadening market access, introducing new products, and deepening its partner network across life sciences, food and nutrition, and bioindustrial sectors.
Competitive Landscape
Pro stress-test →DYADI competes in the synthetic biology and recombinant protein production space. Direct competitors include other protein expression platform companies like Genentech/Roche, Lonza, and Intrinsic Therapeutics. Cultivated/alternative protein companies (Upside Foods, Perfect Day) represent adjacent competitive applications for DYAI's transferrin products. The company's proprietary C1 and Dapibus platforms differentiate it via animal-free, cost-effective production.
Industry Context
DYADIC INTERNATIONAL INC operates in Biotechnology - Protein Engineering & Expression Platforms.
Key facts
Founded: 1979 · Headquarters: Jupiter, Florida, US · Employees: N/A · Revenue: $1.1M (Q1 2026, TTM basis extrapolates ~$4.4M annualized) · Market cap: N/A